Top

Journal of Diabetes & Metabolic Disorders

Published in:

01-06-2020 | Research article

Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regulated at the transcriptional level

Authors: Neelam Srivastava, Angelo B. Cefalu, Maurizio Averna, Rai Ajit K. Srivastava

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2020

Abstract

Objectives

ATP-binding cassette transporter A1 (ABCA1) is a key player in the reverse cholesterol transport (RCT) and HDL biogenesis. Since RCT is compromised as a result of ABCA1 dysfunction in diabetic state, the objective of this study was to investigate the regulation of ABCA1 in a stably transfected 293 cells expressing ABCA1 under the control of cAMP response element.

Methods

To delineate transcriptional and posttranscriptional regulation of ABCA1, 293 cells were stably transfected with the full length ABCA1 cDNA under the control of CMV promoter harboring cAMP response element. cAMP-mediated regulation of ABCA1 and cholesterol efflux were studied in the presence of 8-Br-cAMP and after withdrawal of 8-Br-cAMP. The mechanism of cAMP-mediated transcriptional induction of the ABCA1 gene was studied in protein kinase A (PKA) inhibitors-treated cells.

Results

The transfected 293 cells expressed high levels of ABCA1, while non-transfected wild-type 293 cells showed very low levels of ABCA1. Treatments of transfected cells with 8-Br-cAMP increased ABCA1 protein by 10-fold and mRNA by 20-fold. Cholesterol efflux also increased in parallel. Withdrawal of 8-Br-cAMP caused time-dependent rapid diminution of ABCA1 protein and mRNA, suggesting ABCA1 regulation at the transcriptional level. Treatment with PKA inhibitors abolished the cAMP-mediated induction of the ABCA1 mRNA and protein, resulting dampening of ABCA1-dependent cholesterol efflux.

Conclusions

These results demonstrate that transfected cell line mimics cAMP response similar to normal cells with natural ABCA1 promoter and suggest that ABCA1 is a short-lived protein primarily regulated at the transcriptional level to maintain cellular cholesterol homeostasis.

Srivastava RA, Srivastava N. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol Cell Biochem. 2000;209:131–44.CrossRef

Srivastava N. ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis. Mol Cell Biochem. 2002;237:155–64.CrossRef

Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336–45. https://doi.org/10.1038/11905.CrossRefPubMed

Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347–51. https://doi.org/10.1038/11914.CrossRefPubMed

Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352–5. https://doi.org/10.1038/11921.CrossRefPubMed

Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25–31. https://doi.org/10.1172/jci8119.CrossRefPubMedPubMedCentral

Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci U S A. 1999;96:12685–90.CrossRef

Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet. 2000;24:192–6. https://doi.org/10.1038/72869.CrossRefPubMed

McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A. 2000;97:4245–50.CrossRef

10.

Cavelier C, Rohrer L, von Eckardstein A. ATP-binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res. 2006;99:1060–6. https://doi.org/10.1161/01.RES.0000250567.17569.b3.CrossRefPubMed

11.

Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem. 2001;276:33969–79. https://doi.org/10.1074/jbc.M102503200.CrossRefPubMed

12.

Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108:303–9. https://doi.org/10.1172/jci12517.CrossRefPubMedPubMedCentral

13.

Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A. 2002;99:407–12. https://doi.org/10.1073/pnas.012587699.CrossRefPubMed

14.

Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun. 1999;257:29–33. https://doi.org/10.1006/bbrc.1999.0406.CrossRefPubMed

15.

Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, et al. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol Cell Biol. 2003;23:7756–66.CrossRef

16.

Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001;276:38378–87. https://doi.org/10.1074/jbc.M105805200.CrossRefPubMed

17.

Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000;97:12097–102. https://doi.org/10.1073/pnas.200367697.CrossRefPubMedPubMedCentral

18.

Wang Y, Oram JF. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem. 2002;277:5692–7. https://doi.org/10.1074/jbc.M109977200.CrossRefPubMed

19.

Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem. 2018;440:167–87. https://doi.org/10.1007/s11010-017-3165-z.CrossRefPubMed

20.

Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes. 2011;60:2617–23. https://doi.org/10.2337/db11-0378.CrossRefPubMedPubMedCentral

21.

Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23:447–54. https://doi.org/10.1021/tx9003775.CrossRefPubMedPubMedCentral

22.

Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, et al. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes. 2002;51:2922–8.CrossRef

23.

Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res. 2010;51:1719–28. https://doi.org/10.1194/jlr.M003525.CrossRefPubMedPubMedCentral

24.

Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heinecke JW, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes. 2005;54:2198–205.CrossRef

25.

Patel DC, Albrecht C, Pavitt D, Paul V, Pourreyron C, Newman SP, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One. 2011;6:e22142. https://doi.org/10.1371/journal.pone.0022142.CrossRefPubMedPubMedCentral

26.

Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J Biol Chem. 2005;280:35896–903. https://doi.org/10.1074/jbc.M506210200.CrossRefPubMed

27.

Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem. 1996;271:30647–55.CrossRef

28.

Takahashi Y, Miyata M, Zheng P, Imazato T, Horwitz A, Smith JD. Identification of cAMP analogue inducible genes in RAW264 macrophages. Biochim Biophys Acta. 2000;1492:385–94.CrossRef

29.

Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508–11. https://doi.org/10.1074/jbc.M006738200.CrossRefPubMed

30.

Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277:18793–800. https://doi.org/10.1074/jbc.M109927200.CrossRefPubMed

31.

Le Goff W, Zheng P, Brubaker G, Smith JD. Identification of the cAMP-responsive enhancer of the murine ABCA1 gene: requirement for CREB1 and STAT3/4 elements. Arterioscler Thromb Vasc Biol. 2006;26:527–33. https://doi.org/10.1161/01.Atv.0000201042.00725.84.CrossRefPubMed

32.

See RH, Caday-Malcolm RA, Singaraja RR, Zhou S, Silverston A, Huber MT, et al. Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem. 2002;277:41835–42. https://doi.org/10.1074/jbc.M204923200.CrossRefPubMed

33.

Meier JL, Stinski MF. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology. 1996;39:331–42. https://doi.org/10.1159/000150504.CrossRefPubMed

34.

Lashmit P, Wang S, Li H, Isomura H, Stinski MF. The CREB site in the proximal enhancer is critical for cooperative interaction with the other transcription factor binding sites to enhance transcription of the major intermediate-early genes in human cytomegalovirus-infected cells. J Virol. 2009;83:8893–904. https://doi.org/10.1128/jvi.02239-08.CrossRefPubMedPubMedCentral

35.

Back S, Dossat A, Parkkinen I, Koivula P, Airavaara M, Richie CT, et al. Neuronal activation stimulates cytomegalovirus promoter-driven transgene expression. Mol Ther Methods Clin Dev. 2019;14:180–8. https://doi.org/10.1016/j.omtm.2019.06.006.CrossRefPubMedPubMedCentral

36.

Thomas P, Smart TG. HEK293 cell line: a vehicle for the expression of recombinant proteins. J Pharmacol Toxicol Methods. 2005;51:187–200. https://doi.org/10.1016/j.vascn.2004.08.014.CrossRefPubMed

37.

Juszczak RJ, Russell JH. Inhibition of cytotoxic T lymphocyte-mediated lysis and cellular proliferation by isoquinoline sulfonamide protein kinase inhibitors. Evidence for the involvement of protein kinase C in lymphocyte function. J Biol Chem. 1989;264:810–5.PubMed

38.

Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, et al. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem. 2004;279:15091–5. https://doi.org/10.1074/jbc.M313436200.CrossRefPubMed

39.

Bowden K, Ridgway ND. OSBP negatively regulates ABCA1 protein stability. J Biol Chem. 2008;283:18210–7. https://doi.org/10.1074/jbc.M800918200.CrossRefPubMed

40.

Hansen TV, Rehfeld JF, Nielsen FC. Mitogen-activated protein kinase and protein kinase A signaling pathways stimulate cholecystokinin transcription via activation of cyclic adenosine 3′,5′-monophosphate response element-binding protein. Mol Endocrinol. 1999;13:466–75. https://doi.org/10.1210/mend.13.3.0257.CrossRefPubMed

41.

Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53–8. https://doi.org/10.1038/83348.CrossRefPubMed

42.

Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161–71.CrossRef

43.

Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001;98:5306–11. https://doi.org/10.1073/pnas.091021198.CrossRefPubMedPubMedCentral

44.

Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol. 2000;20:1565–71.CrossRef

45.

Park DW, Lee HK, Lyu JH, Chin H, Kang SW, Kim YJ, et al. TLR2 stimulates ABCA1 expression via PKC-eta and PLD2 pathway. Biochem Biophys Res Commun. 2013;430:933–7. https://doi.org/10.1016/j.bbrc.2012.11.135.CrossRefPubMed

46.

Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis. 2009;203:417–28. https://doi.org/10.1016/j.atherosclerosis.2008.07.029.CrossRefPubMed

47.

Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res. 2010;51:1407–15. https://doi.org/10.1194/jlr.M002410.CrossRefPubMedPubMedCentral

48.

Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem. 2009;284:32336–43. https://doi.org/10.1074/jbc.M109.047472.CrossRefPubMedPubMedCentral

49.

Gan X, Kaplan R, Menke JG, MacNaul K, Chen Y, Sparrow CP, et al. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem. 2001;276:48702–8. https://doi.org/10.1074/jbc.M109402200.CrossRefPubMed

50.

Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–41. https://doi.org/10.1172/jci21109.CrossRefPubMedPubMedCentral

51.

Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med. 2005;15:212–9. https://doi.org/10.1016/j.tcm.2005.06.004.CrossRefPubMed

52.

Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A. 2008;105:12224–9. https://doi.org/10.1073/pnas.0802025105.CrossRefPubMedPubMedCentral

53.

Ory DS, Schaffer JE. ApoA-1 in diabetes: damaged goods. Diabetes. 2010;59:2358–9. https://doi.org/10.2337/db10-1040.CrossRefPubMedPubMedCentral

54.

Kotani K, Sakane N, Ueda M, Mashiba S, Hayase Y, Tsuzaki K, et al. Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects. Clin Chim Acta. 2012;414:125–9. https://doi.org/10.1016/j.cca.2012.08.021.CrossRefPubMedPubMedCentral

55.

Iborra RT, Machado-Lima A, Okuda LS, Pinto PR, Nakandakare ER, Machado UF, et al. AGE-albumin enhances ABCA1 degradation by ubiquitin-proteasome and lysosomal pathways in macrophages. J Diabetes Complicat. 2018;32:1–10. https://doi.org/10.1016/j.jdiacomp.2017.09.012.CrossRefPubMed

Title: Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regulated at the transcriptional level
Authors: Neelam Srivastava
Angelo B. Cefalu
Maurizio Averna
Rai Ajit K. Srivastava
Publication date: 01-06-2020
Publisher: Springer International Publishing
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2020
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-020-00517-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Involvement of fat mass and obesity gene (FTO) in the anti-obesity action of Annona muricata Annonaceae: in silico and in vivo studies

Assessing the awareness and care of people with diabetes related to Ramadan fasting; a-cross sectional study from Pakistan

Methylglyoxal and soluble RAGE in type 2 diabetes mellitus: Association with oxidative stress

Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry

The comparison of efficacy and safety between different doses of empagliflozin in insulin-treated type 1 diabetes mellitus patients: a systematic review and meta-analysis protocol

Association Between Metabolic Syndrome and Diabetes Mellitus According to International Diabetic Federation and National Cholesterol Education Program Adult Treatment Panel III Criteria: a Cross-sectional Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials